Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition

Abstract

Hereditary transthyretin amyloidosis with peripheral neuropathy (ATTRv-PN) is an autosomal dominant inherited sensorimotor and autonomic polyneuropathy with over 130 pathogenic variants identified in the TTR gene. Hereditary transthyretin amyloidosis with peripheral neuropathy is a disabling, progressive and life-threatening genetic condition that leads to death in ∼ 10 years if untreated. The prospects for ATTRv-PN have changed in the last decades, as it has become a treatable neuropathy. In addition to liver transplantation, initiated in 1990, there are now at least 3 drugs approved in many countries, including Brazil, and many more are being developed. The first Brazilian consensus on ATTRv-PN was held in the city of Fortaleza, Brazil, in June 2017. Given the new advances in the area over the last 5 years, the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology organized a second edition of the consensus. Each panelist was responsible for reviewing the literature and updating a section of the previous paper. Thereafter, the 18 panelists got together virtually after careful review of the draft, discussed each section of the text, and reached a consensus for the final version of the manuscript.

Resumo

Polineuropatia amiloidótica familiar associada a transtirretina (ATTRv-PN) é uma polineuropatia sensitivo-motora e autonômica hereditária autossômica dominante com mais de 130 variantes patogênicas já identificadas no gene TTR. A ATTRv-PN é uma condição genética debilitante, progressiva e que ameaça a vida, levando à morte em ∼ 10 anos se não for tratada. Nas últimas décadas, a ATTRv-PN se tornou uma neuropatia tratável. Além do transplante de fígado, iniciado em 1990, temos agora 3 medicamentos modificadores de doença aprovados em muitos países, incluindo o Brasil, e muitas outras medicações estão em desenvolvimento. O primeiro consenso brasileiro em ATTRv-PN foi realizado em Fortaleza em junho de 2017. Devido aos novos avanços nesta área nos últimos 5 anos, o Departamento Científico de Neuropatias Periféricas da Academia Brasileira de Neurologia organizou uma segunda edição do consenso. Cada panelista ficou responsável por rever a literatura e atualizar uma parte do manuscrito. Finalmente, os 18 panelistas se reuniram virtualmente após revisão da primeira versão, discutiram cada parte do artigo e chegaram a um consenso sobre a versão final do manuscrito.

Keywords

Amyloidosis - Peripheral Nervous System Diseases - Amyloid Neuropathies, Familial

Palavras-chave

Amiloidoses - Doenças do Sistema Nervoso Periférico - Neuropatias Amiloides Familiares

Authors' Contibutions

MVP, MVG, MCFJ: original draft, manuscript review and editing, these authors contributed equally to this work as co-first authors; WMJ and MWC: manuscript review, editing and supervision, these authors contributed equally to this work as co-senior authors; The other authors contributed equally to the writing of the manuscript, review and editing.

Publication History

Received: 17 October 2022

Accepted: 27 October 2022

Article published online:
14 April 2023

• References

• 1 Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu Rev Biochem 2017; 86: 27-68
• 2 Benson MD, Buxbaum JN, Eisenberg DS. et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25 (04) 215-219
• 3 Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36 (04) 411-423
• 4 Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10 (12) 1086-1097
• 5 Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 2019; 15 (07) 387-404
• 6 Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012; 126 (10) 1286-1300
• 7 Adams D, Ando Y, Beirão JM. et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 2021; 268 (06) 2109-2122
• 8 Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. Ther Clin Risk Manag 2020; 16: 109-123
• 9 Adams D, Samuel D, Goulon-Goeau C. et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123 (Pt 7): 1495-1504
• 10 Coelho T, Maia LF, Martins da Silva A. et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79 (08) 785-792
• 11 Berk JL, Suhr OB, Obici L. et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310 (24) 2658-2667
• 12 Adams D, Gonzalez-Duarte A, O'Riordan WD. et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379 (01) 11-21
• 13 Benson MD, Waddington-Cruz M, Berk JL. et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379 (01) 22-31
• 14 Pinto MV, Barreira AA, Bulle AS. et al. Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arq Neuropsiquiatr 2018; 76 (09) 609-621
• 15 Ando Y, Coelho T, Berk JL. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 8: 31
• 16 Schmidt H, Cruz MW, Botteman MF. et al. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid 2017; 24 (sup1): 111-112
• 17 Parman Y, Adams D, Obici L. et al; European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29 (Suppl 1, Suppl 1) S3-S13
• 18 Inês M, Coelho T, Conceição I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology 2018; 51 3-4 177-182
• 19 Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA 2020; 324 (01) 79-89
• 20 Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995; 60 (06) 512-521
• 21 Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15 (03) 181-186
• 22 Planté-Bordeneuve V, Carayol J, Ferreira A. et al. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 2003; 40 (11) e120
• 23 Saporta MA, Zaros C, Cruz MW. et al. Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families. Eur J Neurol 2009; 16 (03) 337-341
• 24 Waddington-Cruz M, Schmidt H, Botteman MF. et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis 2019; 14 (01) 34
• 25 Schmidt HWC. M.; Botteman, M.F.; Carter, J.A.; Chopra, A.S.; Stewart, M.; Hopps, M.; Fallet, S.; Amass, L. Global prevalence estimates of transthyretin familial amyloid polyneuropathy (ATTR-FAP): a systematic review and projections. The 19th annual European Congress of International Society for Pharmacoeconomics and Outcomes Research. Vienna, Austria2016
• 26 Lavigne-Moreira C, Marques VD, Gonçalves MVM. et al. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population. J Peripher Nerv Syst 2018; 23 (02) 134-137
• 27 Misu Ki, Hattori N, Nagamatsu M. et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 1999; 122 (Pt 10): 1951-1962
• 28 Sobue G, Nakao N, Murakami K. et al. Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system. Brain 1990; 113 (Pt 4): 903-919
• 29 Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86 (09) 1036-1043
• 30 Sekijima Y. Hereditary Transthyretin Amyloidosis: University of Washington, Seattle, Seattle (WA), 1993
• 31 Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293 (5539): 2459-2462
• 32 Bonaïti B, Olsson M, Hellman U, Suhr O, Bonaïti-Pellié C, Planté-Bordeneuve V. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?. Eur J Hum Genet 2010; 18 (08) 948-952
• 33 Koike H, Misu K, Ikeda S. et al; Study Group for Hereditary Neuropathy in Japan. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002; 59 (11) 1771-1776
• 34 Benson MD, Dasgupta NR, Rao R. Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines. Ther Clin Risk Manag 2020; 16: 749-758
• 35 Thomas VE, Smith J, Benson MD, Dasgupta NR. Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease. Neurodegener Dis Manag 2019; 9 (06) 289-299
• 36 Cruz MW, Pinto MV, Pinto LF. et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr 2019; 77 (02) 96-100
• 37 Jacobson DR, Pastore R, Pool S. et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996; 98 (02) 236-238
• 38 Coutinho PDA, Lima JL, Barbosa AR. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG CP, de Freitas AF. ed. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980: 88-98
• 39 Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid 2012; 19 (Suppl 1): 65-67
• 40 Bittencourt PL, Couto CA, Clemente C. et al. Phenotypic expression of familial amyloid polyneuropathy in Brazil. Eur J Neurol 2005; 12 (04) 289-293
• 41 Pinto MV, Pinto LF, Dias M. et al. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry. J Neurol Sci 2019; 403: 1-6
• 42 Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007; 35 (01) 116-118
• 43 Mariani LL, Lozeron P, Théaudin M. et al; French Familial Amyloid Polyneuropathies Network (CORNAMYL) Study Group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015; 78 (06) 901-916
• 44 Koike H, Tanaka F, Hashimoto R. et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012; 83 (02) 152-158
• 45 Dohrn MF, Röcken C, De Bleecker JL. et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 2013; 260 (12) 3093-3108
• 46 Swiecicki PL, Zhen DB, Mauermann ML. et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid 2015; 22 (02) 123-131
• 47 Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75 (03) 408-427
• 48 Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62 (07) 1057-1062
• 49 Coelho T, Sousa A, Lourenço E, Ramalheira J. A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected. J Med Genet 1994; 31 (04) 293-299
• 50 Ikeda S, Hanyu N, Hongo M. et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain 1987; 110 (Pt 2): 315-337
• 51 Adams D, Lozeron P, Theaudin M. et al; French Network for FAP. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012; 19 (Suppl 1): 61-64
• 52 Rapezzi C, Quarta CC, Riva L. et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010; 7 (07) 398-408
• 53 Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail 2019; 6 (06) 1128-1139
• 54 Maurer MS, Hanna M, Grogan M. et al; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68 (02) 161-172
• 55 Garcia-Pavia P, Rapezzi C, Adler Y. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021; 42 (16) 1554-1568
• 56 Queiroz MC, Pedrosa RC, Berensztejn AC. et al. Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients. Arq Bras Cardiol 2015; 105 (05) 503-509
• 57 Gillmore JD, Maurer MS, Falk RH. et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016; 133 (24) 2404-2412
• 58 Simões MV, Fernandes F, Marcondes-Braga FG. et al. Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021. Arq Bras Cardiol 2021; 117 (03) 561-598
• 59 Yamashita T, Ando Y, Katsuragi S. et al. Muscular amyloid angiopathy with amyloidgenic transthyretin Ser50Ile and Tyr114Cys. Muscle Nerve 2005; 31 (01) 41-45
• 60 Pinto MV, Milone M, Mauermann ML. et al. Transthyretin amyloidosis: Putting myopathy on the map. Muscle Nerve 2020; 61 (01) 95-100
• 61 Pinto MV, Dyck PJB, Liewluck T. Neuromuscular amyloidosis: Unmasking the master of disguise. Muscle Nerve 2021; 64 (01) 23-36
• 62 Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol 1997; 81 (04) 295-298
• 63 Gondim FAA, Holanda Filha JG, Moraes Filho MO. Ophthalmological manifestations of hereditary transthyretin amyloidosis. Arq Bras Oftalmol 2022; 85 (05) 528-538
• 64 Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012; 7 (08) 1337-1346
• 65 Ikeda SI, Hineno A, Ichikawa T, Makino M. Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis. Amyloid 2019; 26 (02) 99-100
• 66 Maia LF, Magalhães R, Freitas J. et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015; 86 (02) 159-167
• 67 Sousa L, Coelho T, Taipa R. CNS Involvement in Hereditary Transthyretin Amyloidosis. Neurology 2021; 97 (24) 1111-1119
• 68 Quintanilha GS, Cruz MW, Silva MTT, Chimelli L. Oculoleptomeningeal Amyloidosis Due to Transthyretin p.Y89H (Y69H) Variant. J Neuropathol Exp Neurol 2020; 79 (10) 1134-1136
• 69 Conceição I, González-Duarte A, Obici L. et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2016; 21 (01) 5-9
• 70 Adams D, Suhr OB, Hund E. et al; European Network for TTR-FAP (ATTReuNET). First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016; 29 (Suppl 1, Suppl 1) S14-S26
• 71 Vital C, Vital A, Bouillot-Eimer S, Brechenmacher C, Ferrer X, Lagueny A. Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. J Peripher Nerv Syst 2004; 9 (04) 232-241
• 72 Do Amaral B, Coelho T, Sousa A, Guimarães A. Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid 2009; 16 (04) 232-238
• 73 de Paula Eduardo F, de Mello Bezinelli L, de Carvalho DL. et al. Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy. Neurol Sci 2017; 38 (02) 311-318
• 74 Quarta CC, Gonzalez-Lopez E, Gilbertson JA. et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017; 38 (24) 1905-1908
• 75 Koike H, Hashimoto R, Tomita M. et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011; 18 (02) 53-62
• 76 Obici L, Kuks JB, Buades J. et al; European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016; 29 (Suppl 1, Suppl 1) S27-S35
• 77 Cortese A, Vegezzi E, Lozza A. et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 2017; 88 (05) 457-458
• 78 Kapoor M, Rossor AM, Jaunmuktane Z, Lunn MPT, Reilly MM. Diagnosis of amyloid neuropathy. Pract Neurol 2019; 19 (03) 250-258
• 79 Planté-Bordeneuve V, Ferreira A, Lalu T. et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007; 69 (07) 693-698
• 80 Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalarrondo V, Théaudin M. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother 2016; 17 (06) 791-802
• 81 Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clin Auton Res 2019; 29 (Suppl. 01) 55-63
• 82 Bentellis I, Amarenco G, Gamé X. et al. Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis. Clin Auton Res 2019; 29 (Suppl. 01) 65-74
• 83 Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res 2019; 29 (02) 245-251
• 84 Marques N, Azevedo O, Almeida AR. et al. Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations. J Am Heart Assoc 2020; 9 (19) e016614
• 85 Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73 (22) 2872-2891
• 86 Ando Y, Adams D, Benson MD. et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid 2022; 29 (03) 143-155
• 87 Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 2015; 21 (03) 282-292
• 88 Holmgren G, Steen L, Ekstedt J. et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40 (03) 242-246
• 89 Bittencourt PL, Couto CA, Farias AQ, Marchiori P, Bosco Massarollo PC, Mies S. Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil. Liver Transpl 2002; 8 (01) 34-39
• 90 Holmgren G, Ericzon BG, Groth CG. et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341 (8853): 1113-1116
• 91 Suhr OB, Holmgren G, Steen L. et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995; 60 (09) 933-938
• 92 Ericzon BG, Wilczek HE, Larsson M. et al. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?. Transplantation 2015; 99 (09) 1847-1854
• 93 Beirão JM, Malheiro J, Lemos C. et al. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid 2015; 22 (01) 31-35
• 94 Yerevanian AI, Shu F. Pearls & Oy-sters: Number, Weaker, and Dizzier Due to Transthyretin Amyloidosis After 2 Liver Transplants. Neurology 2021; 96 (07) e1088-e1091
• 95 Coelho T, Merlini G, Bulawa CE. et al. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther 2016; 5 (01) 1-25
• 96 Waddington Cruz M, Benson MD. A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurol Ther 2015; 4 (02) 61-79
• 97 Coelho T, Maia LF, da Silva AM. et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260 (11) 2802-2814
• 98 Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 2016; 23 (03) 178-183
• 99 Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis 2018; 13 (01) 225
• 100 Barroso FA, Judge DP, Ebede B. et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017; 24 (03) 194-204
• 101 Merlini G, Planté-Bordeneuve V, Judge DP. et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 2013; 6 (06) 1011-1020
• 102 Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol 2018; 25 (03) 464-468
• 103 Coelho T, Inês M, Conceição I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology 2018; 91 (21) e1999-e2009
• 104 Maurer MS, Schwartz JH, Gundapaneni B. et al; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379 (11) 1007-1016
• 105 Damy T, Garcia-Pavia P, Hanna M. et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail 2021; 23 (02) 277-285
• 106 Whelan CJSP, Dungu J, Pinney J. et al. GJDaHPN. Tolerability of diflunisal therapy in patients with transthyretin amyloidosis. XIIIth International Symposium on Amyloidosis. Abstract OP 56.2012
• 107 Wixner J, Westermark P, Ihse E, Pilebro B, Lundgren HE, Anan I. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition. Amyloid 2019; 26 (sup1): 39-40
• 108 Ackermann EJ, Guo S, Booten S. et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19 (Suppl. 01) 43-44
• 109 Ackermann EJ, Guo S, Benson MD. et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid 2016; 23 (03) 148-157
• 110 Brannagan TH, Wang AK, Coelho T. et al; NEURO-TTR open-label extension investigators. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol 2020; 27 (08) 1374-1381
• 111 Coelho T, Ando Y, Benson MD. et al. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L_Rx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurol Ther 2021; 10 (01) 375-389
• 112 Suhr OB, Coelho T, Buades J. et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 2015; 10: 109
• 113 Adams D, Polydefkis M, González-Duarte A. et al; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol 2021; 20 (01) 49-59
• 114 Habtemariam BA, Karsten V, Attarwala H. et al. Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clin Pharmacol Ther 2021; 109 (02) 372-382
• 115 Obici L, Cortese A, Lozza A. et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19 (Suppl. 01) 34-36
• 116 Gillmore JD, Gane E, Taubel J. et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med 2021; 385 (06) 493-502
• 117 Suhr OGM, Da Silva AM, Karam CY. et al. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. 2021 Emerging Science Abstracts. Neurology 2021; 96: e2783-e2788
• 118 Monteiro C, Mesgazardeh JS, Anselmo J. et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight 2019; 4 (12) 4